Stability Indicating UHPLC Method, Development and Validation for Estimation of Eltrombopag and Related Impurities in Tablet Dosage form

THARLAPU SATYA SANKARSANA JAGAN MOHAN1,2,*, KHAGGA MUKKANTI4 and HITESH A JOGIA3

1Research & Development, Jawaharlal Nehru Technological University, Kakinada-533003, India.
2Epione Labs Private LTD, Nacharam Industrial Area, Hyderabad-500076, India.
3Janssen Pharmaceuticals, Jogeshwari (E), Mumbai-400060, India.
4Institute of Science & Technology, Jawaharlal Nehru Technological University, Kukatpally, Hyderabad-500085, India.

*Corresponding author E-mail: victoryjagan1@gmail.com

http://dx.doi.org/10.13005/ojc/340262

(Received: January 01, 2018; Accepted: March 05, 2018)

ABSTRACT

A novel, agile, mass compatible, stability indicating isocratic method developed by using ultra high performance liquid chromatographic (UHPLC) for estimation of Eltrombopag along with its impurities in tablet formulation. Achieved a good separation on Agilent SB C8 (50× 3.0 mm, 1.8 μ column and mobile phase composed of acetonitrile and 0.1% glacial acetic acid buffer in the ratio of 60:40 v/v at 0.4 ml/minute flow rate and 25 °C column temperature within runtime of 15 minutes. Eltrombopag was detected at 230 nm. The proposed method proves its stability indicating power by resolving Eltrombopag peak from its process impurities and degradation products with more than resolution 2.0. The proposed method is not only simple but capable to separate its potential degradable. The intended method is efficient to determine assay of Eltrombopag in the existence of its impurities within the same run. The retention time observed for Eltrombopag is about 3.9 minutes. The designed method is validated for precision, accuracy, sensitivity, robustness and specificity parameters according to ICH guidelines. Eltrombopag was exposed to stress conditions in acidic, basic, thermal, water, oxidative, humidity and photo degradation. Noticeable degradation is observed in oxidative hydrolysis.

Keywords: Eltrombopag, Validation, UHPLC, Stability indicating method, Forced degradation, Methanol.

INTRODUCTION

Eltrombopag is an approved drug for adult patients suffering from chronic immune thrombocytopenic purpura (ITP). The symptoms are insufficient response to immune globulins, or splenectomy, corticosteroids and having oral bioavailability. Use of Eltrombopag in lower dose is...
being essential to shorten the bleeding risk by increasing the platelet count and the dose can be adjusted upon the platelet count response. It is also used for thrombocytopenia treatment in patients with hepatitis C virus and chronic liver disease (1-3). Chemically Eltrombopag Olamine is 3’-{(2Z)-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene]hydrazino}-2’-hydroxy-3-biphenylcarboxylic acid - 2-aminoethanol (1:2) (Fig. 1) and the molecular weight of Eltrombopag Olamine is 564.65 and 442.5 for Eltrombopag (4). Few analytical methods reported in the literature for the content estimation of Eltrombopag in drug substance, biological samples using high performance liquid chromatography (HPLC) and Mass Spectroscopy (MS) (5-7). There is one more reported method for the Eltrombopag quantification in pharmaceutical bulk and formulations by using ultra performance liquid chromatography (UPLC) (8). The purpose of this research was to develop an assay method which is stability indicating for estimation of Eltrombopag in a pharmaceutical formulations by using ultra high performance liquid chromatography (UHPLC) and separating its degradants along with process related impurities. To the simplest of our information no methodology is accessible in the literature by separating the impurities, 1, 2, 3 (Fig. 1) using only 15 min. runtime.

The key objective of the current research was to develop a validated reverse phase UHPLC method which is stability indicating for the quantitative estimation of Eltrombopag and its process impurities and possible degradants during forced degradation. In the current study Eltrombopag, three of its process related impurities are: Impurity-1 (Fig. 1b), Impurity-2 (Fig. 1c) and Impurity-3 (Figure 1d).

MATERIALS AND METHODS

Chemicals and reagents

The Eltrombopag active pharmaceutical ingredient and three process related impurities (Impurity-1, Impurity-2 and Impurity-3) and the finished product tablets was gifted by Epione Labs. (Nacharam, Hyderabad, India). Acetonitrile, glacial acetic acid, hydrochloric acid and hydrogen peroxide, sodium hydroxide were procured from Merck & Co, Germany. Ultra pure water used in this study is collected from Milli-Q plus purification system.

Table 1: System suitability data

| Name     | RT (min.) | RRTa | Resolutionb | Tailing Factor | RRFc |
|----------|-----------|------|-------------|----------------|------|
| Imp-1    | 1.081     | 0.28 | -           | 1.3            | 2.11 |
| Eltrombopag | 3.852     | 1.00 | 11.4        | 1.1            | 1.00 |
| Imp-2    | 6.103     | 1.58 | 5.9         | 1.1            | 0.83 |
| Imp-3    | 8.519     | 2.21 | 4.8         | 1.2            | 0.90 |

a Relative retention times (RRT) were calculated against the retention time (RT) of Eltrombopag.
b Resolution was calculated between two adjacent peaks.
c Relative response factor (RRF) was computed against Eltrombopag peak response.
Equipment

An UHPLC system (Make: Shimadzu, Kyoto, Japan) armed with a diode array detector was used. The output signal was processed using Lab solutions software. Samples for thermal stability study were exposed to heat in an oven (Make: Thermolab, India).

Chromatographic conditions

Final separation was obtained on Agilent SB C8 50x 3.0 mm, 1.8 μ column with mobile phase composed of acetonitrile and 0.1% glacial acetic acid buffer (1.0 ml of glacial acetic acid in 1 L of water) in 60:40 v/v ratio and filtered with 0.45µm membrane filter. The mobile phase flow rate was kept at 0.4 mL/min by maintaining the column temperature at 25 °C, monitored at 230 nm detector wavelength. Samples were injected for a run time of about 15 min. with an injection volume of 2 µL. Used methanol as diluent. Calculations were performed by using external standardization methodology.

Standard solution

Eltrombopag 1000 µg/ml standard stock solution is prepared by dissolving the equivalent amount in diluent.

System suitability solution

Further a 0.5 µg/ml of Eltrombopag standard solution was prepared in further dilutions using diluent.

Sample Solution

Crush 20 Tablets to a fine powder and transferred 100 mg of powder equivalent of Eltrombopag in a 100 mL volumetric flask. Diluent of 60 mL was added to it and sonicated for 30 min. with and make up to volume with diluent. Filter the solution using 0.45 µm filter.

A spiked sample solution is prepared by spiking all three known impurities at the concentration of 0.5% with respect to sample concentration of 1000 µg/ml.

Method development and Optimization of the chromatographic conditions

The main objective of the research is to develop a stability indicating method for the separation Eltrombopag and its related compounds by using UHPLC. Several trails were conducted...
during the stability indicating method development using UHPLC for the analysis of Eltrombopag and their related compounds in pharmaceutical tablet formulation. Tried with various compositions of mobile phase which consists of buffer with solvents like acetonitrile and methanol, but the combination of buffer and acetonitrile appeared in a lack of symmetry for Eltrombopag and their related compound peaks. The finest results were obtained in the mobile phase consist of acetonitrile and 0.1% glacial acetic acid buffer (1.0 ml of glacial acetic acid in 1 L of water) in 60:40 v/v ration at flow rate of 0.4 mL/min. using Agilent SB C8 50x 3.0 mm, 1.8 μ column, column temperature of 25 °C using DAD detector at 230 nm, and able to resolve Eltrombopag and its three impurities (Imp-1 to Imp-3) (Fig. 2) by meeting the system suitability requirement with a resolution of more than 2.0 between all adjacent peaks. Evaluated the response factor for the impurities related to Eltrombopag (Table 1). Using the above chromatographic conditions achieved a good separation with a total runtime of 15 minutes.

Eltrombopag shows a significant degradation in peroxide oxidation (Fig. 3b). Eltrombopag was degraded into Imp-1, Imp-2 and unknown impurity at RRT about 1.29 by oxidative hydrolysis. The mass balance found to be more than 95% for the degraded samples in all the stress conditions (Table 2). Verified peak purity for every stress sample solution using HPLC-PDA system and the results found to be passed as per the software acceptance criteria, which demonstrates analyte peak homogeneity (Free from overlapping of peaks).

**RESULTS**

**Method validation**

**Specificity and forced degradation studies**

Specificity shows the ability of the method to quantify the response of the analyte in accompany of its degradation products and free from blank and placebo interference. Likely degradation product will be identified in stress degradation studies indicates the stability indicating nature of the method. Stress degradation studies for Eltrombopag tablets were executed under acidic hydrolysis (For 60 min. in 0.1M HCl at 60 °C), basic hydrolysis (For 60 min. at 60 °C in 0.1 M NaOH), hydrolytic oxidation (For 60 min. in hydrogen peroxide (10%) at 60 °C), and thermal condition (For 12 h at 105 °C), Refluxed at 60 °C with water for about 60 minutes. Exposed the samples to humidity study at 25 °C/ 90 % RH about 15 days and exposed the sample to light of 200 Watt/hours. The samples prepared in the above conditions were filtered with 0.45 μm filter before dilution. Water bath (with temperature controller) was used to carry out the stress degradation studies.

Individual solutions of Eltrombopag and its process impurities were scanned in the range of 200 nm to 400 nm using a diode array detector. Found that all the compounds are showing maximum absorbance at about 230 nm and hence 230 nm was opted for method detection.
Table 2: Stress degradation data of Eltrombopag

| Stress Condition                  | % Degradation | Mass Balance | Peak purity index |
|----------------------------------|---------------|--------------|-------------------|
| Acid (For 60 min. in 0.1M HCl at 60 °C) | 0.04          | 99.6         | 1.000             |
| Base (For 60 min. in 0.1 M NaOH at 60 °C) | 0.14          | 98.7         | 1.000             |
| Peroxide (For 60 min. in H₂O₂ (10%) at 60 °C) | 2.23          | 98.6         | 1.000             |
| Water (at 60 °C, 60 min.)        | 0.05          | 99.5         | 1.000             |
| Thermal (For 12 h at 105 °C)     | 0.05          | 99.5         | 1.000             |
| Humidity (For 15 Days at 25 °C and 90 % RH) | 0.05          | 100.0        | 1.000             |
| Light (200 Watt/h)               | 0.04          | 98.8         | 1.000             |

a Mass Balance = % Degradation + % Assay

**Precision**

Precision study for the intended method was assessed by injecting Eltrombopag sample along with 0.5% level of its three impurities (0.5% of impurity concentration with respect to 1000 mg/mL Eltrombopag) on six individual samples. The percent RSD of spiked Impurities 1, 2, and 3 are less than 5%, proves good method precision (Table 3).

**Linearity**

Linearity of the method was established by preparing a series of six concentrations (i.e., LOQ, 10, 20, 40, 100, and 200%) with 1.0% thought of to be 100% by linear least square analysis method. Correlation coefficient (r), slope and y-intercept for the three impurities are presented in Table 3. The obtained correlation coefficient is more than 0.999, for all impurities indicating a linear response of the method.

Table 3: Regression and precision data for Eltrombopag

| Compound  | LOD (%) | LOQ (%) | Slope (b) | Intercept (a) | Precision (%RSD) | LOQ Precision (%RSD) |
|-----------|---------|---------|-----------|---------------|------------------|----------------------|
| Imp-1     | 0.001   | 0.010   | 404897    | -9088         | 1.0              | 7.0                  |
| Eltrombopag| 0.018   | 0.020   | 191735    | 2850          | 0.9              | 4.4                  |
| Imp-2     | 0.013   | 0.038   | 158891    | 1500          | 0.6              | 6.5                  |
| Imp-3     | 0.012   | 0.035   | 172570    | -303          | 0.8              | 7.0                  |

**Limit of Quantification (LOQ) and Limit of Detection (LOD)**

The LOQ and the LOD for all the three process impurities of Eltrombopag were assessed at the concentrations where the signal-to-noise ratios detected were 3:1 ratio and 10:1 ratio, respectively. LOQ level precision was also determined by analysing six individual consecutive preparations of the three process impurities by calculating the RSD (%) (Table 3).

**Robustness**

Robustness determines the capability of the method to remain unchanged by small planned variations in the method parameters. The conditions studied were flow rate (altered by ±0.05 mL/min.), column temperature (altered by ±5 °C) and organic phase variation (altered by ±10%). Resolution between adjacent peaks is more than 2.0 in all the conditions (Table 5).

**Solution stability**

Standard and test solutions stability were verified by keeping them on benchtop for 48 hours. Both the solutions are found to be stable at benchtop and no significant change was observed for all the three impurities.
Table 4: Accuracy (n=3) data for Eltrombopag

| Level | Imp-1 (%RSD) | Imp-2 (%RSD) | Imp-3 (%RSD) | Eltrombopag (%RSD) |
|-------|--------------|--------------|--------------|-------------------|
| 50%   | 104.8(1.6)   | 100.3(0.5)   | 105.0(2.4)   | 101.5(0.9)        |
| 100%  | 106.6(0.6)   | 102.3(1.2)   | 100.9(1.5)   | 100.8(0.9)        |
| 150%  | 103.7(3.3)   | 100.4(4.0)   | 98.1(3.0)    | 102.1(0.6)        |

Table 5: Robustness data

| Resolution | 0.35 ml/min. | 0.45 ml/min. | 20 °C | 30 °C | 90% ACN | 110% ACN |
|------------|--------------|--------------|-------|-------|---------|----------|
| Imp-1      | -            | -            | -     | -     | -       | -        |
| Eltrombopag| 10.0         | 10.8         | 11.3  | 11.4  | 10.0    | 7.9      |
| Imp-2      | 4.5          | 5.4          | 5.3   | 5.4   | 5.4     | 4.2      |
| Imp-3      | 3.4          | 4.2          | 4.0   | 4.2   | 4.2     | 3.0      |

*Resolution between adjacent peaks was calculated

CONCLUSION

An easy, specific, reliable and mass compatible isocratic method using UHPLC-DAD was developed for the quantitative estimation of Eltrombopag in Tablet formulation. This was the first method for separation and quantification of Eltrombopag and its process related impurities in comparison with reported methodologies. The current method was successfully resolved all the degradants, three known impurities and estimate the active component perfectly. Validated the developed method according to ICH guidelines and found to be specific, linear, accurate, robust, precise, and rugged. Proposed chromatographic method with a short run time of 15 min. permits the analysis of a many samples in a day. The developed methodology has proved the stability-indicating power, and hence it can be used for regular analysis throughout stability studies in quality control laboratories.

ACKNOWLEDGMENT

The authors are grateful to the management of Epione Labs. Pvt. Ltd. for their support. Authors wish to acknowledge the research group for providing the samples for our research.

REFERENCES

1. Deng, Y.; Madatian, A.; Wire, M.B.; Bowen, C.; Park, J.W.; Williams, D.; Peng, B.; Schubert, E.; Gorycki, F.; Levy, M.; Gorycki, P.D. Metabolism and disposition of eltrombopag, an oral, non peptide thrombopoietin receptor agonist, in healthy human subjects, Drug Metab Dispos., 2011, 39(9), 1734–1746.
2. Serebruany, V.L.; Eisert, C.; Sabaeva, E.; Makarov, L. Eltrombopag (Promacta), a thrombopoietin receptor agonist for the treatment of thrombocytopenia: current and future considerations, Am. J. Ther, 2010, 17(1), 68–74.
3. Allred, A.J.; Bowen, C.J.; Park, J.W.; Peng, B.
Williams, D.D.; Wire, M.B.; Lee, E. Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers, *Br. J. Clin. Pharmacol.*, 2011, 72(2), 321-329.

4. https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/promacta.pdf (accessed Jan 1, 2018).

5. Wire, M.B.; Mclean, H.B.; Pendry, C.; Theodore, D.; Park, J.W.; Peng, B. Assessment of the pharmacokinetic interaction between eltrombopag and lopinavir–ritonavir in healthy adult subjects, *Antimicrob. Agents Chemother.*, 2012, 56(6), 2846–2851.

6. Williams, D.D.; Peng, B.; Bailey, C.K.; Wire, M.B.; Deng, Y.; Park, J.W.; Collins, D.A.; Kapsi, S.G.; Jenkins, J.M. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies, *Clin. Ther.*, 2009, 31(4), 764–776.

7. Rambabu, M.; Ramakrishna, G.; Nageswara, R.P.; Sridhar, S.; Srinubabu, M.; Ajitha, M. Liquid chromatography–tandem mass spectrometric assay for eltrombopag in 50 µL of human plasma: A pharmacokinetic study, *J. of Pharm. and Biomed. Ana.*, 2014, 98, 68–73.

8. Mahaboob, B.D.; Venkata, R.G.; Shobha, R.T.; Susithra, E.; Rajasekhar, C. RP-UPLC-MS assay method for eltrombopag: Application in pharmaceuticals, human plasma and urine samples, *Asian J. Chem*, 2015, 27(12), 4615–4619.

9. Monika, B.; Saranjit, S. Development of validated stability indicating assay methods-critical review; *J. of Pharm. and Biomed. Ana*, 2002, 28, 1011-1040.

10. ICH harmonized tripartite guideline, stability testing of new drug substances and products, Q1A (R2), 2003.

11. ICH of technical requirements for the registration of pharmaceutical for the human use, validation of analytical procedures: text and methodology, ICH, Q2 (R1), 2005.